<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841278</url>
  </required_header>
  <id_info>
    <org_study_id>5170383</org_study_id>
    <nct_id>NCT04841278</nct_id>
  </id_info>
  <brief_title>Utility of Combined EUS and ERCP Procedures in the Evaluation of Liver Graft Dysfunction</brief_title>
  <official_title>Utility of Combined EUS and ERCP Procedures in the Evaluation of Liver Graft Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this investigator-initiated study is to determine whether a single-step&#xD;
      session that combines endoscopic ultrasound (which may further include liver biopsy and&#xD;
      needle-guided cholangiography) with endoscopic cholangiopancreatography (ERCP) can facilitate&#xD;
      in the management of liver graft dysfunction. All patients will undergo the same procedural&#xD;
      protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver graft dysfunction can arise from many disease processes, which include biliary&#xD;
      obstruction, rejection, infection and ischemia. Battery of tests, and at times empiric&#xD;
      therapy, is necessary to obtain final diagnosis. This results in waste of time and medical&#xD;
      resources that can lead to delay in care, which may ultimately translate to increase&#xD;
      morbidity and mortality, as well as increase in cost.&#xD;
&#xD;
      In this protocol, the investigators propose utilization of interventional endoscopy for the&#xD;
      diagnosis and treatment of liver graft dysfunction. Use of endoscopic ultrasound (EUS) with&#xD;
      possible liver biopsy and cholangiography, and endoscopic retrograde cholangiopancreatography&#xD;
      in one session may facilitate diagnosis and treatment. All patients enrolled in this protocol&#xD;
      will undergo the same procedural protocol. The quality of care metrics in these patients&#xD;
      (such as length of stay, cost, mortality, etc), will be compared to that of historical&#xD;
      controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    decided not to go ahead with study&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single prospective arm with historical controls as comparator</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to final diagnosis</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Time from first diagnostic test to final diagnosis</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Graft Dysfunction</condition>
  <arm_group>
    <arm_group_label>EUS/ERCP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with liver graft dysfunction enrolled sequentially for proposed protocol: EUS with possible interventions and possible ERCP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS/ERCP</intervention_name>
    <description>EUS with possible interventions, including liver biopsy and/or cholangiography, and possible ERCP. No new experimental procedures are proposed, only new protocol for diagnosis and treatment of liver graft dysfunction.</description>
    <arm_group_label>EUS/ERCP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All hospitalized patients with liver graft dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Thrombocytopenia (platelets &lt;50.000/mL) until corrected&#xD;
&#xD;
          -  Coagulopathy (international normalized ratio (INR) &gt;1.5) until corrrected&#xD;
&#xD;
          -  Use of thrombolytic or anti-platelet agents within 5-7 days of the procedure.&#xD;
&#xD;
          -  Any with known bleeding diathesis will be excluded. (e.g. disseminated intravascular&#xD;
             coagulation (DIC), von-Willebrand disease, hemophilia).&#xD;
&#xD;
          -  Those who had recent prior liver biopsy or EUS/ERCP will be excluded.&#xD;
&#xD;
          -  Those with active bacteremia will be excluded, at least until treated.&#xD;
&#xD;
          -  For this initial study, those with altered GI tract anatomy (e.g. those with&#xD;
             hepaticojejunostomy or gastro-jejunostomy) will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander W Jahng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

